1st Cardiology Department, University of Athens Medical School, Hippokration Hospital, Athens, Greece.
Curr Top Med Chem. 2013;13(13):1548-58. doi: 10.2174/15680266113139990104.
MicroRNAs are a class of evolutionarily small non-coding RNAs of 19 to 25 nucleotides in length, that represent one of the most exciting areas of current medical science as they can regulate a complex regulatory network of gene expression and physiologic processes including differentiation, proliferation and apoptosis in a highly context dependent fashion. Recently, their role in cardiovascular disease and in the regulation of cardiomyocyte size and function, in the action potential, in angiogenesis and in mitochondrial function was recognized. Importantly, they have been evaluated for their prognostic and diagnostic role in heart failure and modification of specific microRNAs levels has been tested as a therapeutic option in experimental heart failure models. In this review article we refer the most emerging evidence, concerning the role of microRNAs in myocardial development in heart failure pathophysiology and prognosis, and their therapeutic implications.
MicroRNAs 是一类长度为 19 到 25 个核苷酸的进化上较小的非编码 RNA，它们是当前医学科学最令人兴奋的领域之一，因为它们可以高度依赖于上下文的方式调节基因表达和生理过程的复杂调控网络，包括分化、增殖和凋亡。最近，它们在心血管疾病以及调节心肌细胞大小和功能、动作电位、血管生成和线粒体功能中的作用得到了认识。重要的是，它们在心力衰竭中的预后和诊断作用已经得到了评估，并且已经在实验性心力衰竭模型中测试了改变特定 microRNAs 水平作为治疗选择的方法。在这篇综述文章中，我们提到了 microRNAs 在心力衰竭病理生理学和预后中心肌发育中的作用的最新研究证据，以及它们的治疗意义。
